Lawrence Eichenfield - Jun 8, 2023 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
VRCA
Transactions as of
Jun 8, 2023
Transactions value $
$0
Form type
4
Date filed
6/12/2023, 09:03 AM
Previous filing
Jun 13, 2022
Next filing
Sep 20, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRCA Stock Option (right to buy) Award $0 +10.4K $0.00 10.4K Jun 8, 2023 Common Stock 10.4K $5.70 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 8, 2023 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date.